We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings
Read MoreHide Full Article
In its upcoming report, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.72 per share, reflecting a decline of 7.7% compared to the same period last year. Revenues are forecasted to be $4.28 billion, representing a year-over-year decrease of 4.4%.
Over the last 30 days, there has been an upward revision of 5% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Teva Pharmaceutical Industries metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Geographic Revenue- International Markets' should arrive at $581.38 million. The estimate indicates a year-over-year change of +4.4%.
The consensus among analysts is that 'Geographic Revenue- United States' will reach $1.88 billion. The estimate points to a change of -24.5% from the year-ago quarter.
The consensus estimate for 'Geographic Revenue- United States- COPAXONE' stands at $59.92 million. The estimate suggests a change of -3.4% year over year.
Analysts' assessment points toward 'Geographic Revenue- United States- BENDEKA and TREANDA' reaching $27.74 million. The estimate indicates a year-over-year change of -20.7%.
Analysts forecast 'Geographic Revenue- United States- AUSTEDO' to reach $674.01 million. The estimate indicates a change of +12.2% from the prior-year quarter.
Analysts expect 'Geographic Revenue- Europe- COPAXONE' to come in at $44.33 million. The estimate points to a change of +0.8% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Geographic Revenue- Europe- Respiratory products' of $55.36 million. The estimate suggests a change of +6.5% year over year.
Analysts predict that the 'Geographic Revenue- International Markets- Generic products (including OTC and biosimilars)' will reach $433.90 million. The estimate points to a change of +3.1% from the year-ago quarter.
It is projected by analysts that the 'Geographic Revenue- International Markets- COPAXONE' will reach $7.88 million. The estimate indicates a change of -1.5% from the prior-year quarter.
The average prediction of analysts places 'Geographic Revenue- United States- AJOVY' at $97.94 million. The estimate suggests a change of +34.2% year over year.
The combined assessment of analysts suggests that 'Geographic Revenue- Europe- Generic products (including OTC and biosimilars)' will likely reach $1.02 billion. The estimate indicates a year-over-year change of +4.2%.
According to the collective judgment of analysts, 'Geographic Revenue- Europe- AJOVY' should come in at $73.94 million. The estimate indicates a change of +12% from the prior-year quarter.
Teva Pharmaceutical Industries shares have witnessed a change of +0.9% in the past month, in contrast to the Zacks S&P 500 composite's +0.9% move. With a Zacks Rank #4 (Sell), TEVA is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings
In its upcoming report, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.72 per share, reflecting a decline of 7.7% compared to the same period last year. Revenues are forecasted to be $4.28 billion, representing a year-over-year decrease of 4.4%.
Over the last 30 days, there has been an upward revision of 5% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Teva Pharmaceutical Industries metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Geographic Revenue- International Markets' should arrive at $581.38 million. The estimate indicates a year-over-year change of +4.4%.
The consensus among analysts is that 'Geographic Revenue- United States' will reach $1.88 billion. The estimate points to a change of -24.5% from the year-ago quarter.
The consensus estimate for 'Geographic Revenue- United States- COPAXONE' stands at $59.92 million. The estimate suggests a change of -3.4% year over year.
Analysts' assessment points toward 'Geographic Revenue- United States- BENDEKA and TREANDA' reaching $27.74 million. The estimate indicates a year-over-year change of -20.7%.
Analysts forecast 'Geographic Revenue- United States- AUSTEDO' to reach $674.01 million. The estimate indicates a change of +12.2% from the prior-year quarter.
Analysts expect 'Geographic Revenue- Europe- COPAXONE' to come in at $44.33 million. The estimate points to a change of +0.8% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Geographic Revenue- Europe- Respiratory products' of $55.36 million. The estimate suggests a change of +6.5% year over year.
Analysts predict that the 'Geographic Revenue- International Markets- Generic products (including OTC and biosimilars)' will reach $433.90 million. The estimate points to a change of +3.1% from the year-ago quarter.
It is projected by analysts that the 'Geographic Revenue- International Markets- COPAXONE' will reach $7.88 million. The estimate indicates a change of -1.5% from the prior-year quarter.
The average prediction of analysts places 'Geographic Revenue- United States- AJOVY' at $97.94 million. The estimate suggests a change of +34.2% year over year.
The combined assessment of analysts suggests that 'Geographic Revenue- Europe- Generic products (including OTC and biosimilars)' will likely reach $1.02 billion. The estimate indicates a year-over-year change of +4.2%.
According to the collective judgment of analysts, 'Geographic Revenue- Europe- AJOVY' should come in at $73.94 million. The estimate indicates a change of +12% from the prior-year quarter.
View all Key Company Metrics for Teva Pharmaceutical Industries here>>>Teva Pharmaceutical Industries shares have witnessed a change of +0.9% in the past month, in contrast to the Zacks S&P 500 composite's +0.9% move. With a Zacks Rank #4 (Sell), TEVA is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .